As of 2024-12-14, the Relative Valuation of Pacira Biosciences Inc (PCRX) is (3.76) USD. This relative valuation is based on P/E multiples. With the latest stock price at 19.86 USD, the upside of Pacira Biosciences Inc based on Relative Valuation is -119.0%.
The range of the Relative Valuation is (20.72) - 20.27 USD.
Note: valuation result may not be accurate due to the company's negative earnings.
| Range | Selected | |
| Trailing P/E multiples | 11.7x - 15.7x | 14.0x |
| Forward P/E multiples | 12.6x - 18.5x | 15.8x |
| Fair Price | (20.72) - 20.27 | (3.76) |
| Upside | -204.3% - 2.1% | -119.0% |
| Date | P/E |
| 2024-12-13 | -11.22 |
| 2024-12-12 | -11.18 |
| 2024-12-11 | -11.48 |
| 2024-12-10 | -11.16 |
| 2024-12-09 | -10.78 |
| 2024-12-06 | -10.88 |
| 2024-12-05 | -10.54 |
| 2024-12-04 | -10.78 |
| 2024-12-03 | -9.42 |
| 2024-12-02 | -10.06 |
| 2024-11-29 | -9.55 |
| 2024-11-27 | -9.40 |
| 2024-11-26 | -9.48 |
| 2024-11-25 | -9.84 |
| 2024-11-22 | -9.91 |
| 2024-11-21 | -9.82 |
| 2024-11-20 | -9.62 |
| 2024-11-19 | -9.45 |
| 2024-11-18 | -9.40 |
| 2024-11-15 | -9.37 |
| 2024-11-14 | -9.25 |
| 2024-11-13 | -9.29 |
| 2024-11-12 | -9.49 |
| 2024-11-11 | -9.88 |
| 2024-11-08 | -9.74 |
| 2024-11-07 | -10.00 |
| 2024-11-06 | -9.98 |
| 2024-11-05 | -9.76 |
| 2024-11-04 | -9.29 |
| 2024-11-01 | -9.36 |
| 2024-10-31 | -9.37 |
| 2024-10-30 | -9.53 |
| 2024-10-29 | -9.70 |
| 2024-10-28 | -9.67 |
| 2024-10-25 | -9.50 |
| 2024-10-24 | -9.61 |
| 2024-10-23 | -9.82 |
| 2024-10-22 | -9.96 |
| 2024-10-21 | -9.79 |
| 2024-10-18 | -9.88 |
| 2024-10-17 | -9.57 |
| 2024-10-16 | -9.39 |
| 2024-10-15 | -9.43 |
| 2024-10-14 | -9.22 |
| 2024-10-11 | -9.16 |
| 2024-10-10 | -8.76 |
| 2024-10-09 | -8.80 |
| 2024-10-08 | -8.84 |
| 2024-10-07 | -9.03 |
| 2024-10-04 | -9.33 |